Alder BioPharma (ALDR) Tops Q4 EPS by 5c

Alder BioPharma (NASDAQ: ALDR) reported Q4 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65).

Expected 2016 Events and Milestones

• Announce top-line 12-week data from the 600-patient Phase 2b double-blind, randomized, placebo-controlled, dose-ranging clinical trial of ALD403 in chronic migraine patients by the end of the first quarter of 2016.
• Announce top-line 12 and 24-week data from the Phase 1 placebo-controlled, multi-dose, clinical trial of ALD403 aimed at quarterly self-administration in healthy volunteers by the end of the first quarter of 2016.
• Announce top-line 24-week data from the 600-patient Phase 2b double-blind, randomized, placebo-controlled, dose-ranging clinical trial of ALD403 in chronic migraine patients mid-year 2016.
• Initiate PROMISE 2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 1) in patients with chronic migraine as the second of the two planned pivotal clinical trials intended to support a BLA submission to the FDA for ALD403 in the second half of 2016.
• Initiate late stage clinical development of a self-injected formulation of ALD403 following completion of the Phase 1 trial.
• Submit an IND application to the FDA for ALD1613, a genetically engineered monoclonal antibody designed to specifically inhibit adrenocorticotropic hormone (ACTH) focusing on two orphan diseases: Congenital Adrenal Hyperplasia and Cushing’s Disease.

For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance